Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
The recent 16% drop in Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) stock could come as a blow to insiders who purchased US$108k worth of stock at an average buy price of US$10.76 over the past 12 ...
Every investor in Impel Pharmaceuticals Inc. (NASDAQ:IMPL) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership.
Impel Pharmaceuticals Inc. (IMPL) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.79 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results